SMStefano Minieri

Stefano Minieri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stefano Minieri has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cognitive screening performance in patients with inflammatory bowel disease in remission: a case-control study

    by Costantino Sgamato, Carmen Ambrosio, Stefano Minieri, Giovanni Zerella, Alba Rocco, Pietro Coccoli, Gerardo Nardone, Debora Compare

    Background: Emerging evidence links inflammatory bowel disease (IBD) to neurological and mood disorders, but cognitive function in this population remains understudied. By using Montreal Cognitive Assessment (MoCA) we screened for mild cognitive impairment (MCI) patients with IBD and healthy controls (HC). Methods: We enrolled a highly selected cohort of 120 patients with IBD in clinical, biochemical, and endoscopic remission (59 with ulcerative colitis [UC] and 61 with Crohn’s disease [CD]) and 115 matched HC. A MoCA score <26 was considered a below-threshold cognitive screening result, not a clinical diagnosis of mild cognitive impairment. The Hospital Anxiety and Depression Scale (HADS) was used to assess current symptoms rather than establish psychiatric diagnoses. Results: MoCA scores <26 were more frequent among patients with IBD than HC (57% vs. 42%, P = .016), even after excluding participants with HADS scores in the probable-symptom range (57.9% vs. 37.5%, P = .009). Mean total MoCA scores did not differ significantly between groups (25.0 vs. 25.3, P = .280). In exploratory subgroup comparisons, patients with UC had lower naming-domain scores than HC (P = .002). In multivariable analysis, age (odds ratio [OR] 1.03, 95% confidence interval [CI] 1.0–1.1; P = .002), IBD diagnosis (OR 3.07, 95% CI 1.4–6.4; P = .003), and years of schooling (OR 0.85, 95% CI 0.7–1.0; P = .030) were independently associated with a MoCA score <26. After excluding participants with HADS scores in the probable-symptom range, IBD diagnosis (OR 2.72, 95% CI 1.1–6.5; P = .025) and years of schooling (OR 0.71, 95% CI 0.6–0.9; P = .001) remained associated with a below-threshold score. Conclusions: In this highly selected sample, IBD was associated with a greater proportion of below-threshold MoCA scores. These findings reflect cognitive performance and do not establish a higher prevalence of cognitive impairment, a causal mechanism, or a rationale for universal screening. Longitudinal studies incorporating diagnostic neuropsychological assessment are needed.

  • Open Access

    Gut Microbiota-Mediated Molecular Events in Hepatocellular Carcinoma: From Pathogenesis to Treatment

    by Costantino Sgamato, Stefano Andrea Marchitto, Debora Compare, Pietro Coccoli, Vincenzo Colace, Stefano Minieri, Carmen Ambrosio, Gerardo Nardone, Alba Rocco

    Background/Objectives: Hepatocellular carcinoma (HCC) is one of the most common causes of cancer and cancer-related death worldwide. Beyond the well-known factors influencing the risk of HCC, experimental data from animal models and observational human studies support a significant role of the gut microbiota (GM) in HCC initiation and progression. Dysbiosis and increased intestinal permeability synergistically disrupt the ‘gut–liver axis,’ exposing the liver to bacterial metabolites and microbial-associated molecular patterns, thereby contributing to hepatocarcinogenesis. While these findings have expanded our understanding of HCC pathogenesis, a critical translational gap persists as most data derive from preclinical settings, with limited validation in large-scale clinical studies. Methods: This narrative review aimed to contextualise the current evidence on the GM-HCC axis and its clinical translatability. A literature search was conducted in PubMed/MEDLINE, Scopus, and Web of Science up to July 2025 using Medical Subject Headings and related keywords, including HCC, GM, dysbiosis, intestinal permeability, gut–liver axis, microbial metabolites, inflammation/immune modulation, and microbiota-targeted interventions (probiotics, antibiotics, and faecal microbiota transplantation). Reference lists of relevant articles were also screened to identify additional studies. Results: Preclinical models consistently indicate that dysbiosis and impaired gut barrier function can promote hepatic inflammation, immune dysregulation, and pro-tumorigenic signalling through microbe-derived products and metabolite perturbations, supporting a contributory role of the GM in hepatocarcinogenesis. In humans, HCC and advanced chronic liver disease are associated with altered microbial composition and function, increased markers of intestinal permeability, and changes in bile acid and other metabolite profiles; however, reported signatures are heterogeneous across cohorts and analytical platforms. Conclusions: The GM is a biologically plausible and experimentally supported contributor to HCC initiation and progression, with potential for biomarker development and therapeutic targeting. However, clinical translation is limited by predominantly preclinical/associative evidence, interindividual variability, and non-standardised microbiome methods. Large longitudinal studies and adequately powered randomised trials are needed to establish causality, validate biomarkers, and determine whether GM modulation improves HCC prevention, detection, stratification, or outcomes.